Product Description
a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer
Mechanisms of Action: LYPD3 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02134197 |
BAY1129980 | P1 |
Terminated |
Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified |
2018-08-30 |
36% |
2019-12-12 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|